Agenus

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Agenus
May 30, 2025, 10:47 | Blog
Richard Goldberg: Agenus Anticipates Interacting with FDA with New Data Coming at ESMO-GI 2025
Richard Goldberg, Chief Development Officer at Agenus, shared a post on LinkedIn: "As many of…
May 29, 2025, 12:19 | Blog
Agenus Addresses Rising Colorectal Cancer Rates in Younger Adults
Agenus shared a post on LinkedIn: "Colorectal cancer is being diagnosed in younger people—those under 50—at…
May 16, 2025, 02:44 | Blog
Agenus will present new data from MSS metastatic colorectal cancer cohort at ESMO GI25
Agenus posted on LinkedIn: "Agenus will present new data from its expanded MSS metastatic colorectal…
May 15, 2025, 17:00 | Opinion
Agenus Bets Big on Botensilimab
In early 2025, Agenus Inc.—long known for its immuno-oncology ambitions—delivered a pivotal update. At its…
May 14, 2025, 11:10 | Blog
Agenus Welcomes Richard Goldberg as Chief Development Officer
Agenus shared a post on LinkedIn: "We are pleased to welcome Dr. Richard Goldberg to Agenus…
May 13, 2025, 07:27 | Insight
Agenus Shared Q1 2025 Financial Results and Immuno-Oncology Pipeline Updates
Agenus shared a post on LinkedIn: "Today we shared our Q1 2025 financial results and…
May 7, 2025, 01:20 | Blog
National Cancer Research Month - Agenus
Agenus shared a post on LinkedIn: "May marks the start of National Cancer Research Month—a time…
May 4, 2025, 12:58 | Drugs
Agenus supports Richard Goldberg’s call for evolving drug development models
Agenus shared a post on X by The Cancer Letter, adding: "As Dr. Goldberg eloquently…
May 2, 2025, 16:17 | Blog
Myriam Chalabi Discusses Neoadjuvant Immunotherapy and NEOASIS Study Findings at AACR25 - Agenus
Agenus shared a post on LinkedIn: "Yesterday at AACR25, Dr. Myriam Chalabi participated in the…
May 1, 2025, 00:23 | Blog
Myriam Chalabi presented the first results from the NEOASIS study at AACR25 - Agenus
Agenus shared a post on LinkedIn: "Today at AACR25, Dr. Myriam Chalabi presented the first…
Apr 26, 2025, 17:30 | Blog
Anthony El-khoueiry is sharing the latest data from botensilimab/balstilimab in HCC at AACR 25 - Agenus
Agenus shared on LinkedIn: "The Agenus team is live at AACR 25, where Dr. Anthony…
Apr 25, 2025, 18:34 | Science
Jemma Arakelyan: Insights on the trial of Balstilimab + Botensilimab in Metastatic NSCLC
Jemma Arakelyan, Medical Oncologist, CEO at the Institute of Cancer and Crisis, shared a post…
Apr 24, 2025, 05:36 | Blog
Agenus to present new insights from Botensilimab Programs at ASCO 2025
Agenus shared a post on LinkedIn: "The Agenus team is heading back to this year’s…
Apr 21, 2025, 14:44 | Blog
Myriam Chalabi to present first results from NEOASIS trial on neoadjuvant BOT/BAL in MSI-H and MSS solid tumors - Agenus
Agenus shared a post on LinkedIn: "Looking ahead to AACR25: Dr. Myriam Chalabi will present…
Apr 19, 2025, 16:44 | Blog
Agenus to Reveal Phase 1 HCC Immunotherapy Data at AACR 2025
Agenus shared on LinkedIn: "Stay tuned for AACR 25, where Dr. Anthony El-khoueiry will present…
Apr 18, 2025, 08:19 | Blog
This is a great explanation of how immunotherapy is different to traditional cancer therapies - FACS-ASPIRE
Foundation for Autoimmune Cancer Support (FACS-ASPIRE) shared a post by Agenus: "This is a great…
Apr 18, 2025, 01:17 | Blog
Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025
Agenus shared a post on LinkedIn: "Stay tuned for AACR25, where Dr. Anthony El-khoueiry will…
Apr 13, 2025, 05:10 | Blog
Agenus - Harnessing the Immune System for Curative Cancer Therapies
Agenus posted on LinkedIn: "Not all cancer treatments work the same way. Immunotherapy harnesses the…
Apr 4, 2025, 09:40 | Blog
Jennifer Buell: BOTENSILIMAB is changing treatment landscape in MSS colon cancer
Jennifer Buell, President and Chief Executive Officer of MiNK Therapeutics and Executive Council at Agenus,…
Apr 3, 2025, 18:28 | Blog
Dr. Steven O'Day Discusses Innovations in Immunotherapy for Colorectal Cancer on "The Top Line" by Fierce Biotech - Agenus
Agenus shared on LinkedIn: "Tune in to 'The Top Line' by Fierce Biotech! Our Chief…
Mar 26, 2025, 13:31 | Blog
The urgent need for transformative solutions in colorectal cancer treatment - Agenus
Agenus shared a post on LinkedIn: "Findings from our Colorectal Cancer In Focus report underscore…
Mar 25, 2025, 11:21 | Blog
Agenus Reveals Colorectal Cancer Survey Findings, Highlighting Need for Treatment Innovation
Agenus posted on LinkedIn: "New insights from our Colorectal Cancer in Focus highlight a critical…
Mar 25, 2025, 08:22 | Blog
Steven O'Day on the latest innovations and the future of immunotherapy
Steven O’Day, Chief Medical Officer at Agenus, joined Chris Hayden in a recent episode of…
Mar 20, 2025, 10:17 | Blog
Agenus released its Colorectal Cancer In Focus report
Agenus shared a post on LinkedIn: "Today, we released our Colorectal Cancer In Focus report,…
Mar 19, 2025, 07:19 | Blog
Breelyn Wilky Discusses Promising Phase 1 Results of BOT/BAL in Advanced Sarcomas - Agenus
Agenus shared a post on LinkedIn: "Breelyn Wilky, sat down with the Journal of Clinical…
Mar 18, 2025, 06:28 | Blog
Agenus CMO about the latest innovations in CRC Care "The Top Line"
Agenus shared a post on LinkedIn: "Tune in to 'The Top Line' by Fierce Biotech! Our…
Mar 11, 2025, 09:56 | Blog
March is Colorectal Cancer Awareness Month
OncoDaily joins the oncology community in raising awareness about colorectal cancer (CRC), a disease that…
Mar 11, 2025, 06:44 | Stories
Dr Benny Johnson's strong message about his wife's cancer diagnosis in this colorectal cancer awareness month
March is recognized as Colorectal Cancer Awareness Month, a disease that is the second leading…
Mar 9, 2025, 04:38 | Blog
Agenus partners with Fight Colorectal Cancer to drive awareness and action for CRC
Agenus posted on LinkedIn: "Colorectal cancer accounts for 10% of cancers worldwide and 7.6% in…
Mar 6, 2025, 07:05 | Blog
Agenus joins Colorectal Cancer Alliance to raise awareness for Colorectal Cancer Awareness Month
Agenus shared a post on LinkedIn: "This Colorectal Cancer Awareness Month, we stand with Colorectal…
Mar 2, 2025, 11:54 | Blog
Recognizing Colorectal Cancer Awareness Month - Agenus
Agenus shared a post on LinkedIn: "Colorectal cancer (CRC) is the second leading cause of…
Feb 26, 2025, 09:26 | Blog
New translational insights on immune activation in refractory gastric cancer presented at AACRIO25 - Agenus
Agenus shared a post on LinkedIn: "Yesterday at AACRIO25, we presented new translational insights demonstrating…
Feb 16, 2025, 15:08 | Opinion
Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer
Garo Armen, PhD, a philanthropist and biotech leader, made the following address during the Second…
Feb 12, 2025, 07:20 | Blog
How new evaluation methods are helping to better capture the impact of immunotherapy - Agenus
Agenus posted on LinkedIn: "Our Chief Medical Officer Dr. Steven O'Day explains how new evaluation…
Feb 3, 2025, 14:53 | Blog
Meet Janki Bharwada, Associate Medical Monitor of Agenus
Agenus posted on LinkedIn: "Meet Janki Bharwada, Associate Medical Monitor. Janki is passionate about putting…
Jan 30, 2025, 10:48 | Blog
The potential of BOT/BAL for patients who previously had limited treatment options - Agenus
Agenus shared a post on LinkedIn: "Breaking News: Today, we announced the publication of new…
Jan 29, 2025, 07:24 | Science
Justin Stebbing: Botensilimab Plus Balstilimab in Patients With Relapsed/Refractory Metastatic Sarcomas
Justin Stebbing, Professor of Biomedical Sciences at Anglia Ruskin University (ARU), shared his recent article on…
Jan 28, 2025, 16:44 | Oncolibrary
New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas
In this Summary, we discuss the new paper published in JCO on Botensilimab and Balstilimab,…
Jan 27, 2025, 08:22 | Science
Benny Johnson: BOT/BAL in chemotherapy refractory MSS mCRC with no active liver metastases
Benny Johnson, Senior Medical Director at Agenus, shared his recent article on LinkedIn: "Don’t miss our…
Jan 27, 2025, 07:20 | Blog
Dhan Chand: BOT + BAL is redefining the treatment paradigm in colorectal cancer
Dhan Chand, Vice President of Research at Agenus, shared a post on LinkedIn: "BOT +…
Jan 25, 2025, 15:56 | Blog
No recurrences in MSS colorectal cancer with BOT/BAL neoadjuvant immunotherapy: NEST Trial updates from ASCOGI25
The NEST Trial, conducted by Agenus, was presented with latest updates at the ASCO GI…
Jan 23, 2025, 12:00 | Blog
Agenus announced new data highlighting BOT/BAL across multiple lines of treatment in Colorectal Cancer
Agenus shared on LinkedIn: “Today, we announced new data highlighting BOT/BAL across multiple lines of…
Jan 16, 2025, 15:02 | Insight
Agenus will be presenting new data on BOT/BAL at ASCO GI 2025
Agenus shared a post on LinkedIn: “Attending ASCO GI this month? We will be presenting…
Jan 11, 2025, 14:14 | Blog
Looking forward to attending the J.P. Morgan 43rd Annual Healthcare Conference - Agenus
Agenus shared a post on X: "Our team is looking forward to attending the J.P.…
Jan 6, 2025, 14:59 | Insight
Breakthroughs in immunotherapy by Steven O’Day and Alexander Eggermont
Agenus shared a post on LinkedIn: "A little over a year ago, we launched our…
Dec 22, 2024, 09:40 | Dialogues
Botensilimab: A Novel Anti-CTLA- 4 Therapy Effectively Treats Refractory Colorectal Cancers
Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer by OncoDaily was held from…
Dec 21, 2024, 10:35 | Insight
30 Years of Leadership in Immuno-Oncology - Agenus
Agenus shared on LinkedIn: “For 30 years, we have been at the forefront of immuno-oncology.…
Dec 21, 2024, 10:09 | Dialogues
Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market
Interview with Mikhail Groubman, By the Editor-in-Chief of OncoDaily, Gevorg Tamamyan Mikhail Groubman is the…
Dec 20, 2024, 22:35 | Blog
Jennifer S. Buell: Transforming cancer care through innovation in immuno-oncology
Jennifer S. Buell, President and Chief Executive Officer at MiNK Therapeutics, posted the following on…
Dec 20, 2024, 13:21 | Insight
Agenus has Announced Five Presentations at 2025 ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
Presentations will showcase new data reinforcing BOT/BAL’s potential across different lines of treatment in colorectal…
Dec 17, 2024, 17:03 | Blog
Honored to participate in the inaugural Global Cancer Movement: Challenging the Status Quo in Colorectal Cancer - Agenus
Agenus shared a post on LinkedIn: "We were honored to participate in the inaugural Global…
Dec 15, 2024, 11:51 | Blog
Dhan Chand: Honored to have presented at the Global Cancer Movement Conference
Dhan Chand, Vice President of Research at Agenus, reshared a post on LinkedIn by OncoDaily,…
Dec 14, 2024, 15:49 | Career
FairJourney Biologics has appointed Marc van Dijk as the new Chief Scientific Officer of Antibody Discovery and Engineering
FairJourney Biologics recently appointed Marc van Dijk as the new Chief Scientific Officer of Antibody…
Dec 13, 2024, 16:45 | Insight
Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL
Agenus and Tanner Pharma announced a collaboration to provide expanded access to botensilimab (BOT) and…
Dec 10, 2024, 07:33 | Insight
Gevorg Tamamyan: 80 speakers and around 450 participants from 30 countries
Gevorg Tamamyan, Editor-in-chief of OncoDaily, shared a post on LinkedIn: “80 speakers and around 450…
Dec 1, 2024, 11:11 | Blog
Agenus supports the CRCCI in addressing critical gaps in Colorectal Cancer Care
Agenus reshared a post by Fight Colorectal Cancer  on LinkedIn, adding: "Agenus is proud to…
Nov 22, 2024, 21:20 | Blog
Agenus joins Pancreatic Cancer Action Network in raising awareness
Agenus shared a post on LinkedIn: "Today is World Pancreatic Cancer Day and Agenus is…
Nov 17, 2024, 07:39 | Blog
Dhan Chand: Collaboration and innovation in cancer treatment at SITC 2024
Dhan Chand, Vice President of Research at Agenus, posted on LinkedIn: “Curing cancer requires more than innovative…
Nov 13, 2024, 15:07 | Blog
Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development
Agenus: Transforming Cancer Treatment with BOT/BAL While Strengthening Financial Foundations Agenus has announced its third-quarter…
Nov 9, 2024, 14:03 | Blog
OncoInfluencers to Follow on Social Media: Dr. Dhan Chand
We’re excited to feature Dr. Dhan Chand, a leader in cancer immunology and immunotherapy, as…
Nov 9, 2024, 10:50 | Blog
Dhan Chand: Excited to share our latest research at SITC2024
Dhan Chand, Vice President of Research at Agenus, posted on LinkedIn: "Excited to share our…
Nov 8, 2024, 12:37 | Positive
Jennifer Buell: Pioneering Leadership in Biotechnology
Dr. Jennifer Buell is a prominent figure in the biotechnology industry, currently serving as the…
Nov 7, 2024, 12:17 | Blog
Supporting Colorectal Cancer Alliance’s National Blue Hope Bash - Agenus
Agenus shared on LinkedIn: “This past weekend, Agenus was proud to support Colorectal Cancer Alliance’s…
Oct 29, 2024, 21:00 | Positive
Steven O'Day: At the Forefront of Immunotherapy
Dr. Steven O'Day, an immunotherapy pioneer and medical oncologist, is the Chief Medical Officer at…
Oct 25, 2024, 12:34 | Blog
Find out more about immunotherapy with Agenus
Agenus shared a post on LinkedIn: "Receiving a cancer diagnosis can be overwhelming and filled with…
Oct 23, 2024, 14:59 | Blog
Spotlight on Innovation: Dhan Chand, VP of Research at Agenus
Agenus shared on LinkedIn: “Meet Dhan Chand, our Vice President of Research. Dhan believes that…
Oct 22, 2024, 14:57 | Insight
Joseph Grossman: Botensilimab is effective against Tumors Poorly Responsive to Conventional Immunotherapy
Joseph Grossman, Vice President of Early Clinical Development at Agenus,  shared a post on LinkedIn: "The…
Oct 19, 2024, 11:27 | Blog
Thank you, STAT, for another great summit! - Agenus
Agenus posted the following on LinkedIn: “Thank you, STAT, for another great summit! Our team…
Oct 17, 2024, 09:15 | Blog
Looking forward to Dr. Steven O'Day’s Eureka Moment talk at STAT Summit - Agenus
Agenus shared on LinkedIn: "Agenus has arrived at the STAT Summit! We’re looking forward to…
Oct 15, 2024, 11:59 | Blog
Celebrate 30 years of innovation with Agenus
Agenus shared on LinkedIn: "We’re on a mission to harness the power of the immune system to bring therapies…
Oct 7, 2024, 15:21 | Positive
Agenus CEO Dr. Garo Armen Honored with WITSA Eminent Person 2024 Award for Cancer Immunotherapy Breakthrough
Dr. Garo Armen, CEO and Chairman of Agenus Inc., Massachusetts-based leading immuno-oncology biotech, has been…
Oct 7, 2024, 06:49 | Blog
Agenus team at SITC’s 39th Annual Meeting in Houston
Agenus posted on LinkedIn: "We’ll be attending the Society for Immunotherapy of Cancer (SITC)’s 39th…
Oct 5, 2024, 15:31 | Insight
Advancing early detection and treatment: Agenus supports breast cancer awareness month
Agenus shared a post on LinkedIn: “The National Breast Cancer Foundation, Inc. reports that more…
Sep 27, 2024, 16:57 | Blog
Rethinking how we measure cancer immunotherapies at STAT Summit - Agenus
Agenus shared the following on LinkedIn: “We’re proud to sponsor this year’s STAT Summit, focused…
Sep 27, 2024, 12:14 | Blog
Proud to sponsor this year’s STAT Summit - Agenus
Agenus shared on LinkedIn: "We’re proud to sponsor this year’s STAT Summit, focused on delivering…
Sep 24, 2024, 16:52 | Blog
Assessment of the safety and efficacy of Balstilimab in combination with Botensilimab for NSCLC - Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: ''Assessment of the safety and efficacy…
Sep 20, 2024, 14:47 | Blog
That’s a wrap on ESMO2024 - Agenus
Agenus shared a post on LinkedIn: "That’s a wrap on ESMO2024. Our team had a great…
Sep 20, 2024, 11:44 | Blog
Angela V. Hafner promoted to Director of External Innovation at Agenus
Angela V. Hafner shared a post on LinkedIn: ''I’m happy to share that I’ve been…
Sep 15, 2024, 00:29 | Insight
Breelyn Wilky on botensilimab and balstilimab for refractory sarcomas at ESMO24
Agenus shared on LinkedIn: “Breelyn Wilky, presented new data at ESMO24 highlighting the potential of…
Sep 10, 2024, 13:38 | Insight
Agenus‘s latest data from the clinical trial of BOT/BAL in refractory sarcomas at ESMO24
Agenus shared on LinkedIn: “The Agenus team is headed to Barcelona for ESMO24. This Friday,…
Sep 5, 2024, 19:44 | Blog
A stage 4 young-onset cancer survivor speaks about the increase in colon cancer in young adults - Agenus
Agenus shared a post on LinkedIn: "Did you know, colorectal cancer has become the leading…
Sep 4, 2024, 11:47 | Dialogues
Dr. Benjamin Schlechter on Botensilimab: Practice-changing Drug | Most Promising Cancer Drugs 2024
In this episode of OncoDaily Interviews, Dr. Benjamin Schlechter, a distinguished medical oncologist at the…
Aug 29, 2024, 15:56 | Blog
Schedule a meeting with Agenus at ESMO24
Agenus shared on LinkedIn: "Attending ESMO24 in Barcelona from September 13-17? Our Medical Affairs team…
Aug 25, 2024, 20:10 | Blog
Urgent need for new therapies for colorectal cancer patients with MSS disease - Agenus
Agenus posted on LinkedIn: "Andrew Wortmann, Creative Director at Fight Colorectal Cancer, emphasizes the urgent…
Aug 10, 2024, 13:39 | Insight
Botensilimab’s effectiveness against tumours poorly responsive to conventional immunotherapy
Justin Stebbing shared a post on LinkedIn:  “Congratulations to Dhan Chand and the Agenus team…
Aug 10, 2024, 11:58 | Insight
Botensilimab: A Revolutionary Fc-Enhanced CTLA-4 Inhibitor Transforming Cancer Immunotherapy
In the rapidly evolving landscape of oncology, we are witnessing remarkable advancements in various treatment…
Aug 9, 2024, 07:16 | Blog
Botensilimab’s mechanism of action and potential in addressing treatment-resistant cancers
Botensilimab is an investigational human Fc-enhanced CTLA-4 blocking antibody designed to boost both innate and…
Aug 7, 2024, 09:20 | Blog
Shushan Hovsepyan: Honored to interview Nils Eckardt
Shushan Hovsepyan shared a post by OncoDaily on LinkedIn, adding: ''I had the honor of…
Aug 2, 2024, 10:05 | Insight
Marianne Pearson about the urgent need for innovative treatment options for Colorectal cancer patients - Agenus
Agenus shared on LinkedIn: "Colorectal cancer is the second leading cause of cancer death in…
Aug 2, 2024, 08:47 | Dialogues
Driving Change in Oncology: the Vision of the Chief Medical Affairs Officer of Agenus
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the largest and most…
Jul 31, 2024, 03:54 | Blog
What is Immunotherapy? - Agenus
Agenus posted on LinkedIn: "Curious about immunotherapy? Swipe to learn how this innovative treatment boosts…
Jul 29, 2024, 06:38 | Blog
Heart of a Warrior: Jennifer’s Triumphant Fight Against Cancer
Jennifer's story is a testament to strength and resilience. Faced with limited treatment options, she…
Jul 24, 2024, 08:09 | Blog
Gevorg Tamamyan: I urge Agenus to consider Armenia as the first country to register BOT/BAL combination
Gevorg Tamamyan shared on LinkedIn: "As I mentioned in my earlier post, we are ready in…
Jul 19, 2024, 02:00 | Blog
I ask Agenus to consider Armenia as the first country to register the BOT/BAL combination: Gevorg Tamamyan
"~20% ORR and 90% alive at 6 months in comparison to ZERO! How many patients…
Jul 18, 2024, 15:20 | Drugs
Our commitment to seek all possible pathways to make BOT/BAL available to patients is unwavering: Steven O'Day, Agenus CMO
Agenus shared on LinkedIn: "Today, we announced the outcomes of our End-of-Phase 2 meeting and…
Jul 13, 2024, 14:25 | OncoDaily Pulse
OncoDaily Magazine - Inaugural Issue
We are excited to announce that the Inaugural issue of OncoDaily Magazine was launched on…
Jul 13, 2024, 14:15 | Dialogues
I never knew how close to this disease I would eventually become - Benny Johnson’s personal story with cancer
The new issue of OncoDaily Magazine had the privilege to feature an exclusive interview with Dr.…
Jul 13, 2024, 09:41 | Insight
IMMONC - Immune Oncology Research Institute's Experience in Advancing Clinical Cancer Research in Armenia
Cancer affects people across the world regardless of their socioeconomic status. However, low- and middle-income…
Jul 12, 2024, 10:06 | Career
14 individuals recognized for their exceptional contributions in shaping the future of pharmaceutical communications
Fierce Life Sciences Events shared on LinkedIn: "Day 2 of the Pharma PR and Communications…
Jul 11, 2024, 18:15 | Positive
Alexa Buffa named one of 2024's Industry Rising Stars by Fierce Life Sciences Events
Agenus shared on LinkedIn: "Congratulations to our own Alexa Buffa on being named one of…
12
All: 173 Posts: 1 - 100
Special Coverage